Brief: Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
29/04/2025 13:16
April 29 (Reuters) - Perspective Therapeutics Inc CATX.A: PERSPECTIVE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH PSV359 IN A PHASE 1/2A STUDY IN PATIENTS WITH FAP-Α POSITIVE SOLID TUMORS Source text: ID:nGNX1k5kCT Further company coverage: CATX.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Perspective Therapeutics
See all newsPerspective Therapeutics Q2 net loss widens on higher R&D costs
Brief: Perspective Therapeutics Q2 EPS USD -0.22
Brief: Perspective Therapeutics Expands Therapeutic Focus Areas First Patient Dosed With Vmt-Α-Net In The Meningioma Cohort Of A Phase 1/2A Study
Brief: Perspective Therapeutics Q1 EPS USD -0.25
Perspective Therapeutics rises as experimental cancer drug shows promise